The relation between cardiac hypertrophy, shunt size, myocardial contractility, capillary density, adrenergic responsiveness, and neurohumoral stimulation was evaluated in dogs with compensated and decompensated cardiac hypertrophy caused by an infrarenal aorto-caval shunt. Shunt size varied from 5 to 35 mm2 due to an inability to create a uniform size. Dogs that developed heart failure within 4 months had 25±2 mm2 shunts, whereas those that developed it after 4 months had 19±3 mm2 shunts; those that did not develop heart failure had 10±1 mm2 shunts. Hypertrophy developed at the same rate in all the dogs that developed heart failure, which occurred at a critical heart weight (hypertrophy) for a given load (shunt size). In the dogs with heart failure there was a decrease in myocardial contractility (tension=5.7+0.6 vs. 7.3+0.3 g/mm2, p<0.05), a decrease in adrenergic responsiveness (maximal heart rate with isoproterenol=203-+-7 vs. 249±5 beats/min, p<0.01), an increase in circulating neurohormones, and a decrease in urinary sodium excretion (0.4+0.1 vs. 5.0±1.3 meq/3 hr, p<0.01).
The relation between cardiac hypertrophy, shunt size, myocardial contractility, capillary density, adrenergic responsiveness, and neurohumoral stimulation was evaluated in dogs with compensated and decompensated cardiac hypertrophy caused by an infrarenal aorto-caval shunt. Shunt size varied from 5 to 35 mm2 due to an inability to create a uniform size. Dogs that developed heart failure within 4 months had 25±2 mm2 shunts, whereas those that developed it after 4 months had 19±3 mm2 shunts; those that did not develop heart failure had 10±1 mm2 shunts. Hypertrophy developed at the same rate in all the dogs that developed heart failure, which occurred at a critical heart weight (hypertrophy) for a given load (shunt size). In the dogs with heart failure there was a decrease in myocardial contractility (tension=5.7+0.6 vs. 7.3+0.3 g/mm2, p<0.05), a decrease in adrenergic responsiveness (maximal heart rate with isoproterenol=203-+-7 vs. 249±5 beats/min, p<0.01), an increase in circulating neurohormones, and a decrease in urinary sodium excretion (0.4+0.1 vs. 5.0±1.3 meq/3 hr, p<0.01).
None of these abnormalities occurred in dogs with compensated hypertrophy. There were no differences in cardiac capillary density between the control dogs and the dogs with compensated cardiac hypertrophy or heart failure. Thus, it would appear that if heart failure is to develop after an initial toleration of a sudden volume overload, it will develop at a given combination of cardiac hypertrophy and volume overload, with cardiac hypertrophy developing at the same rate in all cases. In this model, once heart failure develops, myocardial contractility and cardiac adrenergic responsiveness are decreased and there is pronounced neurohumoral activation. All these changes are absent in hearts with compensated hypertrophy. (Circulation Research 1990; 66:846-859) T he body optimizes ventricular function in response to a sudden volume overload by neurohumoral activation, which causes an increase in contractility and sodium and water retention.1-6 The new volume load causes the heart to dilate, and the wall stress is normalized by cardiac hypertrophy. [7] [8] [9] [10] [11] [12] In most cases a steady state occurs, and neurohumoral activation largely subsides.'1 A long period of stability can then ensue, but in some cases congestive heart failure finally develops and the effects of neurohumoral activation once again become prominent.1-3 Previous studies have indicated that in patients with a chronic volume overload, congestive heart failure develops when cardiac hypertrophy is inadequate to keep up with cardiac dilatation, thus increasing wall stress. [7] [8] [9] [10] [11] [12] In situations such as aortic insufficiency one can point to progressively severe valvular insufficiency and, thus, increasing volume load as the cause of progressive cardiac dilatation and failure; however, in situations where volume overload remains constant, the cause of sudden failure remains a mystery.
The main purpose of this study was determination of some of the functional and morphological characteristics of the infrarenal aorto-caval shunt experimental model of volume overload. This model resembles the clinical state of chronic functional overload, which some patients do not tolerate. Unlike other experimental studies, a therapeutic diet and drug regimen was started as soon as heart failure was detectable and followed until an uncontrollable state developed. It was hoped that the results of these studies might help in elucidation of the causes of the transition from compensated to decompensated cardiac hypertrophy in chronic volume overload. We found that 1) cardiac hypertrophy developed at the same rate in all the dogs that developed heart failure; 2) heart failure developed at a critical heart weight (hypertrophy) for a given load (shunt size); 3) cardiac hypertrophy developed more slowly or reached a plateau in the dogs that developed compensated cardiac hypertrophy; 4) only a mild decrease in in vitro intrinsic myocardial contractility occurred when heart failure developed; 5) this decrease in contractility probably underestimated the in vivo decrease in contractility because significant cardiac adrenergic dysfunction also occurred once heart failure developed; 6) marked neurohumoral activation and decreased sodium excretion accompanied the development of heart failure; 7) a decrease in capillary density did not contribute to the development of heart failure; and 8) when the shunt is large enough, this model is useful in the study of multiple aspects of congestive heart failure.
Materials and Methods
Sixty male mongrel dogs averaging 28.6±+0.8 kg in weight were used in our study. Twenty dogs served as controls for heart weight-to-body weight ratios, papillary muscle mechanics, and morphometric studies. Aorto-caval shunts were prepared in 40 dogs, and the dogs were separated into three groups: 1) those with compensated cardiac hypertrophy; 2) those with early uncontrollable heart failure or subacute heart failure (<120 days); and 3) those with later uncontrollable heart failure or chronic heart failure (> 120 days). These experimental groups were characterized in terms of their cardiac mass, shunt size, myocardial contractility, adrenergic responsiveness, neurohumoral changes, sodium and water excretion, and morphometric characteristics of the terminal vascular bed. After the dogs had been quarantined for 28-35 days, they were trained for the different protocols. Baseline studies were done 1 week before surgery.
On the day of surgery, anesthesia was induced by the intravenous administration of thiopental sodium (25 mg/kg) and maintained with halothane (1.0-1.5%) in a two-part oxygen/one part nitrous oxide mixture supplied at 10 breaths/min through an endotracheal tube connected to a Harvard respirator (Harvard Apparatus, South Natick, Massachusetts). The abdomen was opened through a midline incision, and the aorta and vena cava were isolated. A 12-to 15-mm side-to-side anastomosis was constructed between the two vessels about 5 cm distal to the renal arteries. 13 The abdomen was closed, and the animals were put into single cages. Meperidine (2 mg/kg) was injected intramuscularly every 8 hours for at least 24 hours postoperatively. The dogs had free access to water and were fed a standard laboratory chow (5.0 g Na/kg, 1 kg/day).
The dogs were followed to one of two end points. If the dog remained stable, all the tests were repeated at 4 months and immediately before death (8-20 months postsurgery). If the dogs developed ascites with or without edema (28 dogs), water access was reduced to 1 1/day, a low-sodium diet was instituted (h. d. diet, Hill, Topeka, Kansas; 0.34 g Na/kg, 1 kg/day), and digoxin (0.125 mg/day), furosemide (40 mg/day), and spironolactone (100 mg/day) were given. With this regimen, nearly all the dogs stabilized for periods ranging from several weeks to several months (1-28 weeks, mean 8 weeks). As the dosages of medications used in this study were relatively small for dogs,14"15 this period of stability may have been due more to sodium and water restriction than to the effects of medication. Once fluid retention could no longer be controlled with this regimen or the general condition of the animal started to deteriorate, as evidenced by lethargy and anorexia, the final tests were done and the dog was sacrificed. The 28 dogs with fluid retention were classified as heart failure dogs; the other 12 dogs were classified as compensated hypertrophy dogs. Seven dogs died of congestive heart failure before any tests could be done. At the time of sacrifice, the animal was weighed, a papillary muscle was excised for in vitro myocardial mechanical studies, and the heart was weighed to assess the degree of hypertrophy. The heart weight-to-body weight ratio was calculated by dividing heart weight (in grams) by body weight at the start of the study (in kilograms). The body weight at the start of the study was used for avoidance of errors in calculation caused by edema in the dogs with heart failure. Percent hypertrophy was calculated as (HW/BWAv-HIW/BWN)100/HW/BWN where HW/BWAV is the heart weight-to-body weight ratio of the aorto-vena caval-shunted dogs and HW/ BWN is the heart weight-to-body weight ratio of the control dogs. The fistula was then removed and the cross section of the shunt assessed by planimetry. Although the initial shunts were similarly constructed, the technical quality of the fistulas varied widely so that there was a significant variation in their surfaces. 4 months and again when a study end point was reached (eight dogs with compensated hypertrophy and seven with heart failure). A small plastic catheter was introduced percutaneously in the cephalic vein of the left forepaw for blood sampling, and the vein was kept open with a continuous perfusion of 0.9% sodium chloride. Again, heart rates were monitored by electrocardiogram (subcutaneous needle electrodes) and were recorded at 10 mm/sec on a Grass 7B polygraph. With the dog resting on a treadmill, baseline heart rate and blood samples were taken. Samples were drawn for measurement of blood lactates, glucose, plasma catecholamines, plasma renin activity, plasma aldosterone, and plasma vasopressin concentrations.
The treadmill protocol consisted of 3-minute stages at a fixed speed of 3.2 km/hr (2 mph) and incremental grades of 0%, 10%, 20%, 30%, 40%, and back to 0% for a recuperative stage. Heart rates, blood lactates, and plasma catecholamines were measured during the last 30 5 .0. The bath was bubbled with a 95%02-5% CO2 gas at a pH of 7.4 and a temperature of 290 C. The base of the muscle was held by a stainless steel clamp, and the other end was tied to a lever identical to that described in detail by Brutsaert et al. 18 The muscles were stimulated to 10% above their threshold at 6 stimuli/min with a Model S-88 stimulator (Grass Instruments) through platinum field electrodes. The preload was adjusted so that the muscle length was at L,. The muscle was stabilized at Lm., for 3 hours; then the total tension was measured during an isometric contraction at a speed of 100 mm/sec on a Model 2400S recorder (Gould, Cleveland, Ohio). After adjustment of the elastic damping of the force-length-velocity lever feedback system to compensate for electromechanical transients,18 the velocity of shortening at zero load (Vm.,) was obtained by abruptly decreasing the load on the muscle at the time of activation (zero load clamp).
The calcium concentration was then increased from 2.54 to 6.35 mM by addition of calcium chloride from a stock solution. The muscles were permitted to stabilize for at least 45 minutes. An isometric contraction and an unloaded contraction (Vma,.) were then recorded. Norepinephrine (Winthrop Laboratories, Aurora, Canada) was added to obtain a 50-,M concentration. The muscles were permitted to stabilize and an isometric and an unloaded contraction (Vm,) were then recorded. The cross-sectional area of the muscle was obtained by dividing the muscle weight by its length, assuming a general cyclindrical shape and a specific gravity of 1.0.
Morphology studies. Samples from left and right ventricular walls were taken from 12 control dogs, six dogs with compensated hypertrophy, and four dogs with acute heart failure. Samples were taken at approximately one third of the distance from the base to the apex of the heart and fixed with a mixture of 1.5% glutaraldehyde buffered to pH 7.4 with phosphate buffer. After fixation and dehydration in alcohol, the samples were embedded in methacrylate resin (Sorval embedding medium). Sections 25 Blood was drawn on EDTA-containing tubes, and plasma was extracted the same day as the experiment by passage through Sep-Pak C-18 cartridges (Waters Chromatography, Milford, Massachusetts). The columns were eluted with a mixture of ethanol and acetic acid and were then evaporated to dryness. The tracer used was PI-labeled rat ANP (Amersham, Canada). The antibody (Peninsula Laboratories, Belmont, California) had 100% cross-reactivity with human a-ANP, rat ANP, and atriopeptin III. Separation was done with a second antibody. Displacement waves were obtained for concentrations of 1-100 pg/tube; sensitivity was 1 pg/tube, and the 50% displacement was 10 pg/tube. Intra-assay and interassay coefficients of variation were less than 10%.
Other Analytical Procedures and Calculations
Blood lactates were measured by use of a commercial kit (Lactate Fully Enzymatic UV-System, Boehringer Mannheim GmbH Diagnostica, Mannheim, West Germany).
Plasma osmolality was determined in duplicate on 250-,ul samples by freezing-point depression (Osmometer 3DII, Advanced Instruments, Needham Heights, Massachusetts). Sensitivity of the instrument is ±1 mosm, and its coefficient of variation at 290 mosm is 0.51%. Plasma for osmometry was always collected on heparin. Osmolal clearance (milliliters per minute) was calculated according to the formula (urinary osmolalityxurinary flow rate)/plasma osmolality, in which urinary and plasma osmolality is measured in milliosmoles per kilogram H20 and urinary flow rate in milliliters per minute.
Statistical Analysis
Data were analyzed by analysis of variance for repeated measurements.26 Subsequently a Dunnett's test was used for determination of whether or not the values obtained in any one of the shunted groups differed from the baseline measurements. When useful, a Newman-Keuls test was used for control of all pairwise comparisons. Levels of p<0.05 were accepted as significant. Results are presented as mean+SEM.
Results
The average time interval from the implantation of the aorto-caval fistula to the sacrifice of the dogs was 143±33 days for dogs in the heart failure group and 324±+39 days for dogs in the compensated hypertrophy group. All of the dogs in the heart failure group showed signs of ascites, sometimes with limb edema, severe pulmonary congestion, and net muscular weight loss. All of the dogs in the second group appeared healthy, with none of these signs. Neither group had significant changes in body weight over the period of the study (from 28.5+ 1.1 to 32.5+ 1.9 kg for the heart failure group and from 28.2+0.7 to 31.2+1.4 kg for the compensated group). In the heart failure group, fluid retention compensated for muscle loss.
Hypertrophy, Shunt Size, and Heart Failure
The dogs that died in heart failure before the final testing were considered in the correlation of the degree of hypertrophy, size of the shunt, and duration of the shunt. For this part of the study, the dogs with heart failure were separated into two groups: 1) those that developed uncontrollable heart failure within 4 months of the surgery (subacute heart failure), and 2) those that developed uncontrollable heart failure more than 4 months after surgery (chronic heart failure). The subacute heart failure group was followed 64±7 days; the chronic heart failure group, 237±42 days; and the compensated group, 324±32 days (Table 1) .
Average shunt sizes were 24.7+1.8, 19.2+2.5, and 9.7+1.1 mm2 for the subacute heart failure, chronic heart failure, and compensated groups, respectively. Heart weight-to-body weight ratio was increased in all of the groups with shunts compared with controls ( Table 1 ). The increase in heart weight-to-body weight ratio was greater in the chronic heart failure and compensated hypertrophy groups than in the subacute heart failure group (Table 1) . When all of the heart failure dogs were considered as a group, a highly significant correlation existed between the duration of the shunt and the degree of hypertrophy (r=0.72, p<0.001) (Figure 1 ). No such correlation existed in the compensated dogs. Although a certain amount of overlap exists, when heart weight-to-body weight ratio is plotted against shunt size (Figure 2 ), a certain separation of the three groups of shunted dogs can be seen. The dogs that developed heart failure did so at a similar product of heart weightto-body weight ratioxshunt size (194+16 for subacute heart failure and 204+29 for chronic heart failure dogs, Table 1 ), whereas dogs that remained compensated had a lower product (99±14). Thus, the development of uncontrollable heart failure is a Table 2 . Plasma norepinephrine concentrations increased once heart failure developed, but they remained unchanged in the presence of compensated hypertrophy. Baseline heart rates were significantly increased in all of the dogs with aorto-caval shunts, particularly in the heart failure group. During all of the tests, heart rate increased significantly after atropine administration, the lowest increase being in the heart failure group. Heart rate remained higher in all the shunted dogs compared with controls. Once heart failure developed, maximum heart rate decreased significantly not only with the maximum dose of isoproterenol used in the standard protocol (8 ,ug) , but also with a dose of 32 ,ug. Furthermore, the chronotropic dose for a 50-beat/ min increase (CD50) was much higher (2.403+0.530
,ug/kg) compared with the control value (0.032±0.003 ,ug/kg). Although the CD50 tended to be higher than the control value in the compensated hypertrophy group, this difference did not reach statistical significance. There were no differences between control maximum heart rates and those obtained in the compensated hypertrophy group. Representative curves are shown in Figure 3 Figure 4 illustrates the effects of exercise testing on the variables measured. The control values were obtained before surgery, and all of the other values were obtained during final testing. Blood samples and heart rate were taken during the 30% grade in the one dog with heart failure that could not complete the exercise protocol. The resting values (at rest before start of exercise test) of the compensated cardiac hypertrophy group were similar to the control group, but in the heart EI control (n = 15) failure group, resting heart rate, plasma renin activity, plasma norepinephrine, and plasma epinephrine values were elevated. During maximal exercise, plasma epinephrine and norepinephrine increased in all groups, with the greatest increase in dogs with compensated or decompensated hypertrophy. Rest- ing blood lactates, plasma vasopressin, and plasma renin activity values were not modified by exercise during control studies, but they increased significantly in dogs with compensated or decompensated hypertrophy, despite normal resting values in the compensated group. During the recuperative stage, except for heart rate, all the variables measured returned to resting values in the compensated group, but in the heart failure group they remained high.
Resting plasma dopamine concentrations were similar in all of the groups (31 +±3 for the control, 36+8 for the compensated, and 50+10 pg/ml for the heart failure group). In the control group, the concentrations did not change during exercise. In all of the groups with shunts, plasma dopamine concentrations increased with exercise (73±18 pg/ml for the compensated and 179±33 pg/ml for the heart failure group). These values did not return to resting levels during the recuperative stage. Plasma aldosterone concentrations were highest in the heart failure 88 .2+4.1 pg/ml, respectively), but there was no change in the heart failure group (98.1±5.0 to 100.8±5.9 pg/ml).
Water load. Figure 5 and Table 3 decreased significantly in the compensated dogs at 2 hours and in the heart failure group at 1 hour ( Figure  5 ). The water load did not significantly change plasma epinephrine or dopamine concentrations. ANP concentrations in the control and heart failure groups were not affected, but they were significantly decreased in the compensated group at 1, 2, and 3 hours.
Sodium excretion was almost totally inhibited in the heart failure group (Table 3) , but the values in the compensated group were similar to the control group. Water excretion, on the other hand, was not significantly different from the control values in either group, although there was a tendency for it to be lower in the heart failure group. Creatinine clearance values in the compensated and heart failure groups were lower than the control values. Osmolal clearance values in both shunted groups were similar to the control values, but minimal urine osmolality was lower in the compensated group.
Papillary Muscle Mechanics
Papillary muscle characteristics were similar in all the groups. Muscle length was 6.9+2.0 mm for the control (n=12), 6 .7±1.8 mm for the compensated group (n=8), and 6.6+1.7 mm for the heart failure group (n = 13). Cross-sectional area was 0.9+0.3 mm2 for the control, 0.8-+0.2 mm2 for the compensated group, and 0.9±0.3 mm2 for the heart failure group.
At baseline calcium (2.5 mM), tension and maximum rate of tension development (dT/dt) were decreased in the heart failure group, and Vmax was insignificantly decreased (Table 4 ). In the compensated group tension did not decrease, but there was a tendency for dT/dt and Vm,_, to decrease. The addition of calcium did not alter these differences (Table 4) , but the addition of norepinephrine increased the differences between the muscles of the heart failure group and those of the control and compensated groups (Table 4 ). Vm., increased similarly in all the groups after the addition of norepinephrine, but tension and dT/dt increased more in the muscles from the control and compensated groups than in the heart failure group, which indicated a decrease in response of failing myocardium to adrenergic stimulation.
Morphometric Studies
Morphometric results are summarized in Table 5 . Capillary density, radius of the tissue cylinder, and the index of heterogeneity of capillary spacing (log SD) were essentially the same in both left and right ventricles. Cardiac hypertrophy, either in its compensated or failing form, did not significantly influence various indexes of capillary geometry.
Discussion
This study differs from previous animal studies of volume overload in two important ways5,6,13,27-38: 1) In this study, the degree of volume overload varied widely so that the cardiac and neurohumoral response to varying loads could be studied in the same animal model. Only with such a wide variability of overload can the myocardial and neurohumoral profiles and characteristics of varying degrees of hypertrophy and clinical states be properly compared and different abnormalities correlated to one another.
2) The follow-up time of animals with volume overload was longer. Once clinical evidence of heart failure developed, the animals were treated in the same way as patients with heart failure so that there was a closer resemblance to the clinical situations of compensated and end-stage chronic volume overload in humans.
This study indicates that when a sudden volume overload occurs, if it is initially well tolerated, two patterns of cardiac hypertrophy can develop: 1) If the shunt and volume overload are large enough, hypertrophy develops at a constant rate until heart failure Values are mean+SEM. n, number of dogs; Epi, epimyocardium; Mid, midmyocardium; Endo, endocardium; Log SD, log standard deviation (index of heterogeneity of capillary spacing).
develops, complete with a decrease in myocardial contractility, cardiac adrenergic system dysfunction, and neurohumoral overactivation. Initially, the symptoms and signs of heart failure are controllable with conventional therapy; however, uncontrollable heart failure eventually develops when a critical heart weight (hypertrophy) for a given shunt size (volume overload) occurs. 2) When the shunt is smaller, compensated cardiac hypertrophy occurs with no obvious decrease in contractility or Vm,.,, and with normal adrenergic responsiveness and only mild or no neurohumoral abnormalities. A decrease in capillary density does not contribute to the decrease in myocardial contractility or to the development of heart failure in this model.
The typical changes found in human congestive heart failure (decreased contractility, decreased adrenergic responsiveness, and increased neurohumoral stimulation) were found in all the dogs with heart failure. Why this occurred sooner and with less hypertrophy in dogs with larger shunts than in those with smaller shunts remains speculative. A more rapid development of myocardial hypertrophy in dogs with larger shunts was not a factor, as hypertrophy developed at the same rate in all the dogs that eventually developed heart failure. One possibility is that the development of cardiac hypertrophy was unable to keep pace with the more rapid occurrence of ventricular dilatation in the dogs with the larger shunts, and the resulting abnormally high level of wall stress precipitated the changes in myocardial mechanics, adrenergic responsiveness, and neurohumoral stimulation. Certainly the importance of such geometric changes would be compatible with the results found in human studies of volume overload caused by aortic and mitral insufficiency7-12 and with those of a previous study of ventricular function in this model of overload.13 These studies have shown heart failure and decreased myocardial contractility to occur when wall stress increases. A second possibility is myocardial ischemia caused by the increase in work load in dogs with large shunts.39 A decrease in coronary reserve and the development of frank ischemia and myocardial dysfunction during exercise have already been demonstrated in this animal model of volume overload even before overt heart failure develops. 35 The compensated dogs had the same degree of hypertrophy as the dogs that developed congestive heart failure more than 4 months after receiving their shunt. However, their rate of development of hypertrophy was slower, and few or none of the abnormalities that existed in the dogs with heart failure were present. Because serial echocardiographic assessments of cardiac size were not done in this study, it is also possible that a similar rate of hypertrophy existed in the two groups and that after reaching a new steady state, hypertrophy ceased to increase. Furthermore, the possibility that some of the dogs with compensated hypertrophy would have eventually developed chronic heart failure remains. In fact, the degree of hypertrophy present in some of the dogs and the relationship between hypertrophy and heart failure demonstrated in the Framingham study40 suggest that this would have been the case.
When heart weight-to-body weight ratio (hypertrophy) was plotted against shunt size (increased load), there was a clear separation between the dogs that developed compensated hypertrophy and the dogs that developed subacute heart failure. However, there was some overlap between the dogs that developed chronic heart failure and the other two groups, suggesting that the development of heart failure in these dogs may have been influenced by other factors, such as earlier or later neurohumoral activation or adrenergic dysfunction. The degree of neurohumoral activation has been shown to vary widely from one patient with heart failure to another'-3 and may have influenced the development of clinical decompensation in our dogs, much as it has been shown to do in humans.4' Furthermore, planimetry of shunt size does not perfectly reflect the volume of blood shunted, and since a certain degree of fibrosis and distortion of the shunt may have occurred during the study, our terminal measurements may have been an incomplete reflection of the overall shunt size throughout the study.
Morphometric Studies
Morphometric evaluation of the coronary capillary density was done to test the frequently proposed postulate that decreased capillary density contributes to the transition from cardiac hypertrophy to cardiac failure. Our data do not support this hypothesis. Capillary density was basically the same in all the regions of the normal hearts and the hearts with compensated hypertrophy as well as in hearts with subacute failure. The same applies to the second oxygen determinant, heterogeneity of capillary spacing (log SD), which remained virtually unchanged. We can conclude that at least under present experimental conditions, the transition from cardiac hypertrophy to cardiac failure occurred in the absence of significant changes in the geometry of the capillary network.
The finding of unchanged capillary density in hypertrophic hearts is at variance with most of the reports in the literature (see our review42). Most of the preceding studies, however, were based on the pressure-overload model of cardiac hypertrophy. Similar studies on volume-overload hypertrophy report a much smaller decrease in capillary density than the decrease found in hearts with the same degree of hypertrophy but caused by pressure overload. For instance, Thomas et a143 reported a significant but relatively small (10%) decrease in capillary density in the subendomyocardial region of volumeoverloaded hypertrophic left ventricles of dogs, with no changes in the midmyocardial and subepimyocardial regions. Incidentally, their values of capillary densities in canine myocardium were identical to those found in the present study. Similarly, in a previous study we found a decrease in capillary density only in the subendocardial region of rat hearts rendered hypertrophic by a volume overload produced by an aorto-caval fistula.44 A possible explanation of the differences in capillary densities between volume and pressure-overload cardiac hypertrophies may be found in a recent paper of Gerdes and coworkers.45 They studied structural remodeling of cardiac myocytes in rats with aortocaval fistulas. These authors reported an increased length of the isolated myocytes to be responsible for most of the cardiac hypertrophy in these animals. In contrast, pressure-overload hypertrophy was mainly characterized by an increased thickness of the cardiac myocytes accompanied by a decreased capillary density.
Finally, the heterogeneity of capillary spacing, determined by the domain method, is the first reported value of this important characteristic of the capillary geometry in the canine heart. Log SD in canine hearts from our experiments was significantly lower than the values we found using the same method in the rat heart."' Thus, dog hearts have slightly lower capillary density than rat hearts, but the distribution of the capillaries is more homogeneous.
Myocardial Mechanics
Studies of isolated papillary muscles and trabeculae showed that intrinsic myocardial contractility decreased once uncontrollable heart failure developed. These results are at odds with those of Carey et al,38 who found no decrease in contractility in studies of papillary muscles from cats with chronic volume overload caused by atrial septotomy. These differences may be due to the ventricle of origin of the muscles studied. In the work of Carey et al,38 right ventricular muscles were studied, whereas in the present research left ventricular muscles were used.
In a previous study we demonstrated that myocardium from the right ventricle of hearts from dogs with chronic volume overload caused by an infrarenal aorto-caval shunt maintained its contractility better than myocardium from the left ventricle.46 Also, clinically, the right ventricle tolerates volume overload better than does the left ventricle, possibly because of different loading conditions. Alternatively, the load induced by atrial septotomy may be insufficient to cause the development of heart failure and decreased contractility.
The fact that Vmax remained normal or near normal despite a significant decrease in other indexes of contractility suggests than chronic volume overload has less effect on Vma, than do other models of hypertrophy and heart failure. 47 it to be decreased.28-30 These differences are probably the result of varying shunt sizes, time of followup, loading conditions, and neurohumoral activation. It would appear that before the development of heart failure, ventricular function is normal or increased due to an increase in adrenergic drive.33 Once heart failure develops, contractility appears to remain normal for some time before it finally decreases in response to a combination of increased wall stress13 and decreased adrenergic responsiveness.28-30 In our study intrinsic myocardial contractility was only slightly decreased despite a longer follow-up period. However, the evaluation of in vitro intrinsic myocardial contractility in our study may have grossly underestimated in vivo ventricular dysfunction because of a number of factors not considered in vitro. 1) In this model there are widespread adrenergic abnormali-ties that reduce the ability of the heart to respond to stress and that are only incompletely considered in vitro. 2) In vivo there is the risk of myocardial ischemia and increased wall stress, which is not evaluated in vitro. 3) Because the in vitro studies were done at slow stimulation rates (6/min) and low temperature (290 C), it is possible that more important differences could be found under more physiological conditions. 4) It is possible that residual digoxin may have minimized the decrease in contractility in muscles from dogs with heart failure.52 Since only half the recommended dose of digoxin was used in our study15 and the animals were sacrificed at least one half-life and usually two half-lives after the last dose,16 it is unlikely that residual digoxin had a major effect on contractility.
Adrenergic Responsiveness
The decrease in f3-adrenergic responsiveness observed in dogs that developed heart failure may have been a contributory factor to its development.
In these dogs, plasma catecholamines were increased at rest and further increased to very high concentrations during exercise, suggesting that an increased sympathetic tone not only played an important role in supporting circulatory function but was also a major mechanism by which these dogs responded to stress.
In a previous study, we demonstrated cardiac nerve dysfunction in these dogs once heart failure developed.53 This probably occurred because of depletion of myocardial neuronal norepinephrine storage. In this study, we demonstrated that the chronotropic response to both exogenous and endogenous adrenergic stimuli was decreased once heart failure developed. These results are at odds with those of Newman,30 who found the chronotropic response to both isoproterenol and norepinephrine injections to be normal in these dogs. Because his studies were done in anesthetized dogs with little or no overt clinical evidence of heart failure, his findings may have been more in keeping with the results in our compensated dogs or, alternatively, his results may have been influenced by the sodium pentobarbital that he used. 54 Thus, Newman's results may not necessarily relate to results from our study. The only other study done in conscious dogs in the model we used showed a decrease in chronotropic response to both norepinephrine and isoproterenol. 55 As in previous in vitro studies of failing myocardium in humans,56,57 there was a decrease in contractile adrenergic responsiveness in myocardium from dogs with heart failure. The exact mechanism for these changes remains to be determined, but it would appear that it is largely limited to tension-related indexes as Vmax responded normally to the addition of norepinephrine in all the muscle groups. Results from our study support three previous in vivo studies in the aorto-caval model that found a decrease in cardiac contractile responsiveness to isoproterenol and norepinephrine once heart failure developed. [28] [29] [30] No significant abnormalities in adrenergic responsiveness were found in dogs with compensated hypertrophy. This was true for both in vitro and in vivo studies. The insignificant increase in CD50 in these dogs probably reflected higher resting heart rates rather than true adrenergic abnormalities.
Neurohumoral Changes
The typical neurohumoral changes found in congestive heart failure and their effects on sodium excretion were present in this aorto-caval model of heart failure.1-6,41 Previous studies have shown that when the aorto-caval shunt is first opened, there is an initial stimulation of neurohormones, which in turn leads to sodium and water retention, volume expansion, and development of a new steady state.5658 Neurohormonal concentrations then return to baseline concentrations.6 '58 In our study we demonstrated that when congestive heart failure develops, neurohumoral stimulation and sodium retention occur once again. The increase in circulating neurohormones found in our study may have been at least partially due to sodium and water restriction and to the use of diuretics when obvious signs of ascites and shortness of breath developed.59'60 However, sodium and water retention and the use of diuretics were not the only causes of neurohumoral stimulation, as these interventions tend to decrease circulating catecholamines,58 and circulating catecholamines were markedly elevated in our dogs. Our assessment of the effects of neurohumoral stimulation on sodium and water excretion may have underestimated the true impairment present in these dogs because our studies were done at rest and the dogs had much more neurohumoral stimulation on exertion. Dogs with heart failure had to call on all their neurohumoral reserves to respond to a stress such as exertion.
The compensated dogs responded to the stress of exercise with no untoward effects. Their neurohumoral responses were similar to those of the control dogs except for plasma epinephrine and norepinephrine, which increased further. Whether or not this increase and the decrease in creatinine clearance found during water loading reflected the effects of the aorto-caval shunt or a decrease in cardiac reserve remains uncertain. However, the major differences between dogs with compensated hypertrophy and those with heart failure indicated that the findings in the heart failure group were not the result of the shunt surgery itself Conclusions It would appear that if a sudden volume overload is well tolerated, it will lead to one of two patterns of cardiac hypertrophy. Uncontrollable heart failure will eventually develop, if the shunt is large. Exactly when this occurs depends on a combination of shunt size, its duration, and a critical heart weight for a given load. Heart failure is accompanied by a mild decrease in intrinsic contractility, which is worsened by decreased adrenergic responsiveness and excessive neurohumoral activation. A decrease in cardiac capillary density does not contribute to the development of heart failure. If the shunt is smaller, compensated cardiac hypertrophy develops, but it is not accompanied by the abnormalities found when heart failure develops.
